Changing Concepts: Menopausal Hormone Therapy and Breast Cancer

Por Chlebowski, Rowan T., Anderson, Garnet L.
Publicado em 2012

Menopausal Hormone Therapy and Cancer: Changing Clinical Observations of Target Site Specificity

Por Chlebowski, Rowan T., Anderson, Garnet L.
Publicado em 2014

Menopausal hormone therapy and breast cancer mortality: clinical implications

Por Chlebowski, Rowan T., Anderson, Garnet L.
Publicado no Ther Adv Drug Saf (2015)

Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative

Por Anderson, Garnet L, Burns, Carolyn J, Larsen, Joseph, Shaw, Pamela A
Publicado no Clin Trials (2016)

Use of Alternative Time Scales in Cox Proportional Hazard Models: Implications for Time-Varying Environmental Exposures

Por Griffin, Beth Ann, Anderson, Garnet L., Shih, Regina A., Whitsel, Eric A.
Publicado em 2012

Lessons Learned From the Women’s Health Initiative Trials of Menopausal Hormone Therapy

Por Rossouw, Jacques E., Manson, JoAnn E., Kaunitz, Andrew M., Anderson, Garnet L.
Publicado em 2013

Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women

Por Bodelon, Clara, Anderson, Garnet L., Rossing, Mary Anne, Chlebowski, Rowan T., Ochs-Balcom, Heather M., Vaughan, Thomas L.
Publicado em 2011

Heart Rate Variability, Ambient Particulate Matter Air Pollution, and Glucose Homeostasis: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative

Por Whitsel, Eric A., Quibrera, P. Miguel, Christ, Sharon L., Liao, Duanping, Prineas, Ronald J., Anderson, Garnet L., Heiss, Gerardo
Publicado em 2009

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women

Por Matsuno, Rayna K., Costantino, Joseph P., Ziegler, Regina G., Anderson, Garnet L., Li, Huilin, Pee, David, Gail, Mitchell H.
Publicado em 2011

Ambient Fine Particulate Matter Exposure and Myocardial Ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative (EEAWHI) Study

Por Zhang, Zhu-ming, Whitsel, Eric A., Quibrera, P. Miguel, Smith, Richard L., Liao, Duanping, Anderson, Garnet L., Prineas, Ronald J.
Publicado em 2009

Bead-based ELISA assays for validation of ovarian cancer early detection markers

Por Scholler, Nathalie, Crawford, Meghan, Sato, Alicia, Drescher, Charles W., O’Briant, Kathy C., Kiviat, Nancy, Anderson, Garnet L., Urban, Nicole
Publicado em 2006

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage

Por Hardikar, Sheetal, Song, Xiaoling, Kratz, Mario, Anderson, Garnet L., Blount, Patricia L., Reid, Brian J., Vaughan, Thomas L., White, Emily
Publicado em 2014

Optimal Cutoffs of Obesity Measures in Relation to Cancer Risk in Postmenopausal Women in the Women's Health Initiative Study

Por Heo, Moonseong, Kabat, Geoffrey C., Strickler, Howard D., Lin, Juan, Hou, Lifang, Stefanick, Marcia L., Anderson, Garnet L., Rohan, Thomas E.
Publicado no J Womens Health (Larchmt) (2015)

Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule

Por Drescher, Charles W., Shah, Chirag, Thorpe, Jason, O'Briant, Kathy, Anderson, Garnet L., Berg, Christine D., Urban, Nicole, McIntosh, Martin W.
Publicado em 2013

Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers

Por Thorpe, Jason D., Duan, Xiaobo, Forrest, Robin, Lowe, Kimberly, Brown, Lauren, Segal, Elliot, Nelson, Brad, Anderson, Garnet L., McIntosh, Martin, Urban, Nicole
Publicado em 2007

SINGLE AGENT CARBOPLATIN VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT OVARIAN CANCER: FINAL SURVIVAL RESULTS OF A SWOG (S0200) PHASE 3 RANDOMIZED TRIAL

Por Markman, Maurie, Moon, James, Wilczynski, Sharon, Lopez, Ana Maria, Rowland, Kendrith M., Michelin, David P., Lanzotti, Victor J., Anderson, Garnet L., Alberts, David S.
Publicado em 2009

Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women

Por McGuire, Valerie, Hartge, Patricia, Liao, Linda M., Sinha, Rashmi, Bernstein, Leslie, Canchola, Alison J., Anderson, Garnet L., Stefanick, Marcia L., Whittemore, Alice S.
Publicado no Cancer Epidemiol Biomarkers Prev (2016)

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Por Freedman, Andrew N., Yu, Binbing, Gail, Mitchell H., Costantino, Joseph P., Graubard, Barry I., Vogel, Victor G., Anderson, Garnet L., McCaskill-Stevens, Worta
Publicado em 2011

Breast Tenderness after Initiation of Conjugated Equine Estrogens and Mammographic Density Change

Por Crandall, Carolyn J., Aragaki, Aaron K., Cauley, Jane A., McTiernan, Anne, Manson, JoAnn E., Anderson, Garnet L., Wactawski-Wende, Jean, Chlebowski, Rowan T.
Publicado em 2011

Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary P...

Por Coleman, Robert L., Moon, James, Sood, Anil K., Hu, Wei, Delmore, James E., Bonebrake, Albert J., Anderson, Garnet L, Chambers, Setsuko K., Markman, Maurie
Publicado em 2014